Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has announced a strategic partnership with Qitan Tech, a Chengdu-based nanopore gene sequencer manufacturer. The collaboration aims to drive technology development, regulatory filings, localization, and industrialization of nanopore gene sequencers in the preimplantation genetic testing (PGT) field.
Nanopore Sequencing Technology and Its Applications
Nanopore sequencing represents the cutting-edge third-generation sequencing technology, which facilitates the analysis of individual nucleic acid molecules. This process involves the passage of a single-stranded nucleic acid molecule through a nanometer-sized protein channel, driven by an electric force and controlled by motor proteins to ensure continuous sequencing. The technology enables real-time recognition of base arrangement information through capturing time-varying current signals, thereby achieving the sequencing of single-stranded nucleic acid molecules.
Qitan Tech’s Market Leadership
Qitan Tech prides itself on offering a self-developed nanopore sequencer, making it the first enterprise in China to market a product that provides real-time sequencing. This technology is particularly beneficial for clinical doctors formulating precise treatment plans and has broad applications in genetic testing.
Preimplantation Genetic Testing (PGT) and Market Outlook
PGT is a crucial field within reproductive medicine that involves testing embryos for genetic abnormalities before implantation in the uterus during IVF procedures. The goal is to identify single gene disorders, chromosomal abnormalities, and mitochondrial disorders. The assisted reproduction market in China is projected to experience a 14.5% compound growth rate by 2025, with the PGT market expected to grow at an accelerated pace of 10%-20%, reaching a value of RMB 350 million (USD 50.77 million) by 2026, largely due to advancements in nanopore sequencing technology.-Fineline Info & Tech
